144: Court Halts FDA Rule on Lab-Developed Tests: What It Means for Pathology

Send us a text Will FDA rules disrupt the way we diagnose diseases? In this episode, I break down a seismic shift in lab medicine: a federal court has vacated the FDA’s controversial rule classifying lab-developed tests (LDTs) as medical devices. This change carries serious implications for innovation, digital pathology, AI-based diagnostics, and small labs across the U.S. 🎧 What You’ll Hear: What LDTs are and why they matter for rare diseases and personalized medicine Why the FDA rul...

Om Podcasten

Aleksandra Zuraw from Digital Pathology Place discusses digital pathology from the basic concepts to the newest developments, including image analysis and artificial intelligence. She reviews scientific literature and together with her guests discusses the current industry and research digital pathology trends.